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Abstract Cyclooxygenases (COX), prostaglandin E2 (PGE2)
and nitric oxide (NO) are believed to be some of the most
important factors related to colon cancer growth and
metastasis. In this study, we aimed to investigate the
associations between COX-2, PGE2 and NO in co-cultures
of human colon cancer spheroids obtained from different
tumor grades with normal human colonic epithelium and
myofibroblast monolayers. L-arginine (2 mM), a substrate for
nitric oxide synthases (NOS), decreased COX-2 and PGE2
levels, while N
G-nitro-L-arginine methyl ester (L-NAME)
(2 mM), a NOS inhibitor, had no influence on COX-2 and
PGE2 levels but limited tumor cell motility. NS398 (75 μM),
a selective COX-2 inhibitor, had no significant influence on
NO level but decreased motility of tumor cells. COX-2, PGE2
and NO levels depended on the tumor grade of the cells,
being the highest in Duke’s stage III colon carcinoma.
Summing up, we showed that addition of L-arginine at doses
which did not stimulate NO level caused a significant
decrease in COX-2 and PGE2 amounts in co-cultures of
colon tumor spheroids with normal epithelial cells and
myofibroblasts. Any imbalances in NO level caused by
exogenous factors influence COX-2 and PGE2 amounts
depending on the kind of cells, their reciprocal interactions
and the local microenvironmental conditions. The knowledge
of these effects may be useful in limiting colon carcinoma
progression and invasion.
Keywords Nitric oxide.Cyclooxygenase-2.
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Introduction
Colorectal carcinoma is one of the major causes of cancer
patient mortality worldwide. The development, progression
and metastasis of this carcinoma are a well-defined series of
steps, which among others depend on local nitric oxide
(NO) concentration and over-expression of cyclooxygenase
(COX) enzymes [1–3].
NO is a short-lived molecule required for physiological
functions but also engaged in pathological ones [4]. It can
be produced from exogenous sources such as nitrovasodi-
lators or endogenously from L-arginine by NO synthases
(NOS) [5]. This molecule exhibits a dual role, stimulating
tumor growth and metastasis on the one hand and, on the
other hand, inhibiting neoplasia by its antioxidant action,
inhibition of angiogenesis, and enhancement of vasodila-
tion, differentiation and apoptosis [6]. These effects are
attributed especially to the local NO concentration. At low
levels, NO increases tumor growth and development, while
higher levels of NO (above optimal concentrations) may
express cytotoxic or cytostatic effects [6, 7]. The degree of
tumor malignancy is also linked to the amount and activity
of NOS proteins [8]. It has been shown that the expression
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DOI 10.1007/s12307-011-0063-xof NOS may promote metastatic behavior of tumor cells
[4]. The level of nitrite and nitrate in serum or culture
supernatants can be significantly reduced by application of
L-NAME, a competitive inhibitor of NOS. Its activity is
based on structural similarity to L-arginine, a substrate for
NOS, and competitive inhibition of L-arginine metaboliza-
tion. It has been shown that L-NAME exerts anti-invasive
and anti-metastatic effects on many cancers including colon
carcinoma [9].
Some reports also demonstrate a cross-talk between NO
and NOS levels and COX expression in cancer cells [10].
COX are essential enzymes which catalyze the conversion of
arachidonic acid (AA) to prostaglandins (PGs). Especially
the COX-2 isoform is important in carcinogenesis and opens
new anticancer therapeutic possibilities [11, 12]. Exposure of
various human carcinoma cell lines to COX-2 inhibitors has
been shown to induce tumor cell apoptosis in laboratory in
vitro tests [13]. It has been shown that the selective COX-2
inhibitor NS398 may in a dose-dependent manner inhibit
proliferation and induce death in many carcinomas including
colon cancer [14]. COX-2-derived bioactive prostaglandins,
especially PGE2, have a direct effect on cancer cells by
increasing their motility and metastatic potential [15].
However, PGE2 is one of the main pro-inflammatory factors,
which is elevated in colorectal cancers and promotes their
development by inducing cell proliferation and inhibiting
apoptosis [16, 17]. Therefore, selective inhibitors of COX-2
may also block PGE2 generation minimizing its colorectal-
tumor-promoting effects.
Selective inhibition of COX-2 and PGE2 production and
influencing NO synthesis in the tumor microenvironment
may represent important goals for prevention or therapy of
colon cancers. The aim of the present study was to
determine the reciprocal relations among NO, COX-2 and
PGE2 in co-cultures of human colon tumor spheroids
derived from different tumor grades with normal human
colonic epithelium or myofibroblast monolayers in the
presence of selective inhibitors of NOS (L-NAME) or
COX-2 (NS398) and after the addition of a substrate for
NOS (L-arginine).
Materials and Methods
Cell Culture
Human colon adenocarcinoma cell lines HT29 (ATCC No.
HTB-38) derived from grade I tumor, LS180 (ATCC No.
CL-187) from grade II tumor and SW948 (ATCC No. CCL-
237) from grade III tumor were cultured in RPMI 1640
medium supplemented with 10% fetal calf serum (FCS)
(Gibco
TM, Paisley, UK) and antibiotics (100 U/ml penicillin
and 100 μg/ml streptomycin) (Sigma, St. Louis, MO, USA)
at 37°C in a humidified atmosphere with 5% CO2.
Human normal colon myofibroblasts CCD-18Co (ATCC
No. CRL-1459) and normal epithelial cells CCD 841 CoTr
(ATCC No. CRL-1807) were cultured in RPMI 1640+
DMEM (1:1) medium (Sigma) supplemented with 10%
FCS at 37°C (CCD-18Co) or 34°C (CCD 841 CoTr) in a
5% CO2/95% air atmosphere.
Preparation of Tumor Cell Spheroids
Tumor cell spheroids were prepared by the liquid overlay
method, as described previously [18]. In brief, tumor cell
suspension (200 μl) at a density of 2×10
5 cells/ml in RPMI
1640 medium supplemented with 10% FCS was plated on
1% agarose-coated 96-multiwell culture plates (4×10
4
cells/well). After 4 days’ incubation at 37°C in a humidified
atmosphere with 5% CO2, the cells formed spheroids.
Co-Culture of Tumor Spheroids with a Monolayer
of Normal Cells
Tumor spheroids were harvested with glass pipettes from
the agarose-coated microplates and transferred into a Petri
dish filled with warm RPMI 1640 medium. After 5 min
washing, 5 spheroids each were transferred onto confluent
monolayers of myofibroblasts and colon epithelial cells in
24-well tissue culture plates in RPMI 1640 medium
supplemented with 2% FCS and incubated at 37°C in a
humidified atmosphere with 5% CO2. Such co-cultures
were designed to reflect different stages of tumor metastasis.
Parallel experiments with tumor spheroids or normal cell
monolayers alone as culture controls were performed. After
24 h of culture, supernatants and cellular lysates were
collected and stored at −80°C until estimation of the amounts
of NO, PGE2 and COX-2.
Exposure of Cells to L-arginine, L-NAME and NS398
After 24-h incubation of the cells in RPMI 1640 with 10%
FCS, the medium was discarded and fresh RPMI 1640
containing2%FCSandL-arginine(2mM)(Sigma),L-NAME
(2 mM) (Sigma) and NS398 (Sigma) (75 μM) was added.
The incubation with the mentioned substances was
performed for 24 h. Culture supernatants and cell lysates were
collected and stored in −80°C for no longer than 3 months.
Cell Migration Assessment
Tumor cells were plated at 5×10
5 cells/ml on 4 cm culture
dishes (Nunc). After formation of monolayers, culture was
scratched with a pipette tip (P300), the medium was
188 R. Paduch, M. Kandefer-Szerszeńdiscarded and the cells were rinsed twice with PBS. Next, a
fresh culture medium was applied and the distance of cell
migration into the wound area after 24 h was estimated in the
control and the cultures treated with L-arginine, L-NAME
and NS398. The plates were stained with the May-
Grünwald-Giemsa method. The observation was performed
in an Olympus BX51 System Microscope (Olympus Optical
CO., LTD, Tokyo, Japan) and the micrographs were
prepared using the analySIS® software (Soft Imaging
System GmbH, Münster, Germany). The results are a mean
distance of migration to 5 selected wound areas taken
from 4 micrographs.
ELISA Assay
The level of human PGE2 was tested immunoenzymatically
(ELISA) using a commercially available kit (Cayman
Chemical Company, Ann Arbor, MI, USA) according to the
manufacturer’s instruction. The optical density at 405 nm was
determined using a microplate reader (Molecular Devices
Corp., Emax, Menlo Park, CA, USA). The concentrations of
PGE2 in the analyzed samples were calculated on the basis
of a standard curve. The detection limit was 15 pg/ml.
Nitric Oxide (NO) Measurement
Nitrate, a stable end product of NO was determined in
culture supernatants by a spectrophotometric method based
on the Griess reaction. Briefly, 100 μl of supernatant was
plated in 96-well flat-bottomed plates in triplicate and
incubated with 100 μl of Griess reagent (1% sulfanilamide/
0.1% N-(1-naphthyl)ethylenediamine dihydrochloride)
(Sigma) in 3% H3PO4 (POCH Gliwice, Poland) at room
temperature for 10 min. The optical density was measured
at 550 nm using a microplate reader. A standard curve was
performed using 0.5–25 μM sodium nitrite (NaNO2) for
calibration.
Immunoblotting
Total lysate of the treated cells was prepared by adding
150 μl of SDS-loading buffer with protease inhibitor
cocktail (Sigma) directly to the cells cultured on 24-well
plates and detaching them with a cell scraper. The
protein concentration was determined using a BCA
TM
Protein Assay Kit (Pierce Biotechnology, Rockford, IL,
USA).
The extracts were boiled for 5 min at 95°C and
centrifuged at 10.000 rpm for 10 min at 4°C. 15 μl of each
protein sample was then loaded onto a 9% SDS-
polyacrylamide gel. Following electrophoresis, the proteins
were electrotransferred onto Immobilon-P transfer mem-
branes (Millipore, Bedford, MA, USA). The membranes
were blocked with 5% skimmed milk for 1 h at room
temperature and probed with primary goat anti-COX-2
IgG polyclonal antibody (Santa Cruz Biotechnology, Inc.) for
Table 1 Colon tumor cell migration assay. The quantitative results of the measurement of migration distances after colon tumor cells treatment
with L-arginine, NS398 and L-NAME
Cell culture Inductor Cell migration distance as compared
to wounded monolayer (μm)
Cell migration distance (%) as compared to
migration of control, non-treated cells (100%)
% of inhibition of
tumor cell migration
HT29 Wounded monolayer 742±11 ––
Non-treated control 390±30 100% –
L-arginine 440±32 85.8% 14.2%
L-NAME 593±33 42.3% 57.7%
NS398 693±49 13.9% 86.1%
LS180 Wounded monolayer 802±19 ––
Non-treated control 385±26 100% –
L-arginine 497±32 73.1% 26.9%
L-NAME 605±55 47.2% 52.8%
NS398 659±48 34.3% 65.7%
SW948 Wounded monolayer 1031±36 ––
Non-treated control 623±57 100% –
L-arginine 689±65 83.82% 16.2%
L-NAME 765±66 65.2% 34.8%
NS398 922±35 26.7% 73.3%
COX-2 and PGE2 Cross-Talk with NO 1892 h. After washing in PBS/1% Tween 20 (TBS-T), the
membranes were labeled with alkaline phosphatase
conjugated donkey anti-goat IgG-AP secondary anti-
bodies (Santa Cruz Biotechnology, Inc) for 1 h at room
temperature. After washing with TBS-T, the membranes
were visualized with alkaline phosphatase substrates (5-
bromo-4-chloro-3-indolyphosphate and nitroblue tetrazolium)
(BCIP/NBT) (Sigma) in color development buffer (100 mM
Tris with 5 mM Mg
2+ at pH 9.5). As an endogenous
control to ensure the same protein loading for each
sample, we used β-actin.
Densitometric Analysis
Semiquantitative densitometric analysis of the bands was
carried out with the Bio-Profil Bio-1D Windows Application
Wounded monolayer
L-arginine addition
NS398 addition 
742±11 m 390±30 m
440±32  539±33 m
693±49 m
Control
b  a
L-NAME addition
d  c
e
m
Fig. 1 The effect of L-arginine
(2 mM), L-NAME (2 mM) and
NS398 (75 μM) on the
migration capacity of colon
tumor HT29 cells. a wounded
monolayer, b tumor cell
migration after 24 h in control
culture, c tumor cell migration
after 24-h incubation with
L-arginine, d tumor cell
migration after 24-h incubation
with L-NAME and e tumor cell
migration after 24-h incubation
with NS398. Bar=500 μm
190 R. Paduch, M. Kandefer-SzerszeńV.99.03 program. The results were presented as density/
volume of the bands.
Statistical Analysis
Results are presented as means ± SD of three independent
experiments. The data were analyzed using one-way
analysis of variance ANOVA followed by Bonferroni’s
multiple comparison post-hoc test. Differences of p≤0.05
were considered significant.
Immunoblots after semiquantitative densitometry were
calculated using Student’s t-test. p-values lower than 0.05
were considered significant.
Results
In the presented study we analyzed the cross-talk among
NO, COX-2 and PGE2 in co-cultures of human colon
carcinoma spheroids with human normal colonic epithelium
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Fig. 2 a–c Nitric oxide (NO)
production in co-cultures of
colon carcinoma cell spheroids
HT29 (a), LS180 (b) and
SW948 (c) with normal colon
epithelial cells (841CoTr) and
myofibroblasts (18Co) during
24 h of incubation with
L-arginine (2 mM), L-NAME
(2 mM), and NS398 (75 μM).
Exposure of cells to L-arginine
non-significantly enhanced NO
production, while L-NAME
significantly inhibited NO
secretion as compared to an
appropriate sample control.
NS398 had no significant
influence on NO production.
* p≤0.05—a co-culture of
tumor/normal cells compared to
an appropriate monoculture of
normal cells. # p≤0.05—a
culture of tumor and/or normal
cells after treatment compared
to an appropriate non-treated
culture
COX-2 and PGE2 Cross-Talk with NO 191and myofibroblasts mimicking the early steps of colon
tumor cell metastasis.
Cell Viability Analysis
The viability of colon tumor and normal cells was
analyzed by the neutral red (NR) uptake assay and the
MTT test.
Both tests revealed that L-arginine had no effect on the
viability of the tumor and normal cells (data not shown).
Cell Motility Analysis
Tumor cell migration was analyzed using the wound assay
model. The quantitative results of the measurement of
migration distances are presented in Table 1 and Fig. 1a–e.
We found that treatment of colon tumor cells with NS398
reduced the migration capacities of the cells. L-NAME also
blocked the migration of tumor cells but the effect was
weaker than that obtained using NS398. Treatment of cells
with L-arginine had no significant influence on the motility
of colon tumor cells.
NO Production
Tumor cell spheroids, especially LS180 and SW948,
produced higher amounts of NO than an equal number of
normal cells cultured as monolayers. Colon epithelial cells
produced similar amounts of NO to myofibroblasts. In co-
cultures, similar concentrations of NO were detected when
HT29, LS180 and SW948 cell spheroids were implanted
onto normal cell monolayers. Generally, in comparison to
tumor cell spheroids (LS180, SW948) cultivated alone, in
co-cultures composed of two kinds of cells a decrease in NO
production was detected. Exposure of the cells to L-arginine
(2 mM) for 24 h enhanced NO production both in the mono-
and co-cultures with significant increase in HT29 and LS180
tumor spheroids and SW948 tumor spheroids co-cultured
with 18Co normal cells. On the other hand, L-NAME
(2 mM) significantly inhibited NO secretion as compared
to an appropriate sample control. Finally, NS398 had no
significant influence on NO production (Fig. 2a–c).
COX-2 Expression
COX-2 expression analysis was performed using the
immunoblotting method (Fig. 3) followed by densitometry
(Fig. 4a–c). We found that in normal colonic epithelium,
there was very low or undetectable COX-2 expression.
Conversely, colon tumor cells over-expressed COX-2
protein. Additionally, normal stromal myofibroblasts were
found to produce COX-2 but in lower amounts than cancer
cells. In tumor spheroids co-cultured with normal myofi-
broblasts, COX-2 expression increased above the sum of
the enzyme level observed in the respective monocultures.
In contrast, in tumor spheroid co-cultures with normal
colonic epithelium very low amounts of COX-2 were
detected. L-arginine added to normal or tumor cell cultures
had no significant influence on COX-2 expression, but in
tumor cells co-cultured with myofibroblasts the amino acid
significantly decreased the enzyme level as compared to a
non-treated co-culture. In mono- and co-cultures treated
with L-NAME, non-significant decrease in COX-2 expres-
sion was detected as compared to a non-treated co-culture
control. The exposure of tumor cells and their co-culture
with myofibroblasts to NS398 resulted in a significant
inhibition of COX-2 expression.
PGE2 Expression
The level of PGE2 closely reflected the expression of
COX-2 protein. Tumor cells produced significantly higher
PGE2 than normal cells. Among the normal cells,
myofibroblasts expressed significantly higher PGE2 than
colonic epithelium. In co-cultures, the prostaglandin level
was lower than the sum of PGE2 produced by the
respective monocultures. Addition of L-arginine had no
significant influence on PGE2 production either in tumor
or normal cells. However, in tumor cell co-cultures with
colonic epithelium the decreases of that prostanoid were
significant as compared to non-treated controls. L-NAME
had no significant influence on PGE2 level, which
remained unchanged or slightly decreased in tumor cells,
normal cells and their co-cultures as compared to untreated
controls. In tumor spheroids, and co-cultures exposed to
NS398, a significant inhibition of PGE2 production was
Fig. 3 Western blot analysis of COX-2 after 24 h of incubation with
L-arginine, L-NAME or NS398 in HT29 colon carcinoma cells,
myofibroblasts and their co-culture. The increase in band density
indicates an increase in protein levels. L-arginine limited COX-2
expression and in tumor cells co-cultured with myofibroblasts the
amino acid significantly decreased the enzyme level as compared to a
non-treated co-culture. L-NAME non-significantly decreased COX-2
expression as compared to a non-treated co-culture control. NS398
caused a significant inhibition of COX-2 expression
192 R. Paduch, M. Kandefer-Szerszeńfound. In normal cell monolayers inhibition of PGE2 after
NS398 addition was non-significant (Fig. 5a–c).
Discussion
Cyclooxygenases (COX) are essential rate-limiting enzymes
catalyzingtheconversionofarachidonicacidtoprostaglandins
(PGs) and other eicosanoids in cells [11, 19]. Three isoforms
of COX have been identified: COX-1 and its spliced version
COX-3 constitutively expressed in tissues and COX-2, which
is regulated by growth factors, cytokines or oncogenes
[20, 21]. It has been clearly shown that COX-2 has tumor-
promoting properties. This enzyme has been found to be
expressed in approximately 40–50% of colonic adenomas
andtobe significantlyover-expressedin80–90% of colorectal
carcinomas [22, 23]. To date, several mechanisms by which
COX-2 contributes to carcinogenesis have been identified.
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Fig. 4 a–c Semiquantitative
results of a densitometric
analysis of the bands of COX-2
protein detected by
immunoblotting performed on
material obtained from
co-cultures of tumor cell
spheroids HT29 (a), LS180
(b) and SW948 (c) with normal
cells. Only co-cultures of tumor
spheroids with colonic
epithelium and myofibroblasts
were analyzed. Note the lack
of COX-2 expression in
normal colonic epithelial cells.
*p<0.05—co-cultures treated
with L-arginine, L-NAME or
NS398 compared to an
untreated co-culture
COX-2 and PGE2 Cross-Talk with NO 193They include inhibition of apoptosis, enhancement of
angiogenesis and invasiveness, modulation of inflammation
and immunosuppression or conversion of procarcinogens to
cancerogenic factors [24]. Finally, COX-2 up-regulation is
closely linked with increased production of PGs, especially
PGE2, which supports tumor growth by induction of
angiogenesis and inhibition of tumor cell apoptosis and
exerts immunomodulating effects via, e.g. T-cell response
inhibition [17, 25, 26].
During tumor development and metastasis, a significant
role is also attributed to nitric oxide (NO). This molecule is
implicated in the regulation of tumorigenesis depending on
its local concentration, tumor stage, local microenviron-
mental conditions or even direct interactions between tumor
and stromal cells.
In this study we tried to find a link between NO and
COX-2 and PGE2 levels in co-cultures of colon cancer
spheroids prepared from tumor cells isolated from differ-
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Fig. 5 a–c PGE2 production in
co-cultures of colon carcinoma
cell spheroids HT29 (a), LS180
(b) and SW948 (c) with normal
colon epithelial cells and
myofibroblasts during 24 h of
incubation with L-arginine,
L-NAME or NS398. ELISA
test. Tumor cells produced
significantly higher PGE2 than
normal cells. Myofibroblasts
expressed significantly higher
PGE2 than colonic epithelium.
L-arginine limited PGE2
production in tumor cells,
myofibroblasts and their
co-cultures. L-NAME had no
significant influence on PGE2
level, which remained
unchanged or slightly decreased
in tumor cells, normal cells and
their co-cultures as compared to
untreated controls. NS398,
inhibited PGE2 production in the
tested cells.
* p≤0.05—a
co-culture of tumor/normal cells
compared to an appropriate
monoculture of normal cells. #
p≤0.05—a culture of tumor and/
or normal cells after treatment
compared to an appropriate
non-treated culture
194 R. Paduch, M. Kandefer-Szerszeńent tumor grades with normal colonic epithelium and
myofibroblasts. We analyzed COX-2 and PGE2 levels in
the presence of an excess concentration of L-arginine, a
substrate for NOS activity and L-NAME, or NS398 as
NOS or COX-2 inhibitors, respectively (Fig. 6).
In our study we used single doses of each agent.
However, it was intended, because we did not want to
analyze the effects depending on different concentrations
of inhibitors or L-arginine but the relationship between
COX-2, NO and PGE2 in specific culture conditions. We
wanted to show that there are changes in specific molecules
concentration or whole cells reaction (motility) when other
moleculesconcentrationislimitedorinhibitedtheiractivity.It
was only to show that such cross-talk among analyzed
molecules exists. The detailed explanation of these observa-
tions, obviously, needs further study.
The selection of the dose of each agent was performed
multistage. On the basis of the literature we selected a few
concentrations. Next, they were tested for their cytotoxicity
because in the further experiments we wanted to show often
slight and delicate changes in specific molecules amounts.
We had to be sure that under any circumstances we did not
influence on cells amount or their viability. Thereafter,
different concentrations were analyzed on their influence on
NO level on normal colon epithelial cells. After that, the
most appropriate concentration of inhibitors and L-arginine
adapted to our experimental model has been selected.
We had to choose either different concentrations of
inhibitors and L-arginine analysis or expand cellular model.
The idea of our study was to analyze the relationship
among selected parameters and therefore only single doses
of inhibitors and L-arginine were used. If different concen-
trations of these agents and different cellular model
combination were analyzed then, as we suppose, the results
would be difficult to explain and in consequence difficult to
understand.
We showed that COX-2 was over-expressed in colon
tumor cells and stromal myofibroblasts but its level was
relatively low in normal colon epithelial cells. Some
authors have shown that COX-2 expression differs depend-
ing on colon tumor grade. Zhang and Sun [11] revealed that
frequencies of COX-2 expression were greater in advanced
colon tumors (Duke’s B-D) than in Duke’s A. Similar
observations were performed by Williams et al. [27], who
showed that higher COX-2 expression was associated with
tumors that were advanced and larger in size. In our study
we confirmed these clinical observations showing in vitro
higher COX-2 and PGE2 amounts in LS180 (grade II) and
SW948 (grade III) cells than in the HT29 (grade I) colon
cancer culture. In co-cultures, similarly to COX-2, also NO
level was comparable to that observed in tumor spheroid
monocultures. The lower amounts of NO in co-cultures
than in tumor cells cultured alone may be partially due to
the general reduction of NO production in tumor cells after
their contact with normal cells [28].
NO is produced from L-arginine, a semiessential amino
acid which by modulating host immune functions causes
variable responses against tumor growth [29, 30]. L-
arginine, in experimental settings, has been shown to exert
anti-tumor effects by reducing tumor size and incidence,
and retarding tumor growth and metastasis [31]. Generally,
L-arginine may reduce chemically induced colorectal
carcinomas influencing host immune system functions
[32]. Supplementation with this amino acid also leads to
increased NO formation by the oxidative deaminase
pathway. In turn, an increased local NO level may induce
cytostasis by inhibiting hyperproliferation of tumor cells or
cytotoxicity in tumor cells by, e.g. formation of toxic
peroxynitrite [33]. Moreover, there is also a cross-talk
between products of the NOS and COX pathways. In our
study, we showed that L-arginine supplementation slightly
increased NO level but had no significant influence on the
Fig. 6 Schematic graph
showing reciprocal relations
among nitric oxide (NO),
nitric oxide synthases (NOS),
cyclooxygenase-2 (COX-2), and
prostaglandin E2 (PGE2)
COX-2 and PGE2 Cross-Talk with NO 195amount of COX-2, and in consequence on PGE2 production
in tumor and normal cell monocultures. The interactions
between NO and COX-2 and PGE2 occur at multiple levels
and therefore it is difficult to unequivocally speculate about
them and give simple answers or solutions. The significant
reduction of PGE2 levels by L-arginine was found in co-
cultures of tumor spheroids with colonic epithelium rather
than with myofibroblasts, which may suggest an important
role of NO in chemoprevention of tumor-epithelial cell
interactions rather than its effect on tumor-stromal devel-
opment, activity and viability. Our results are in agreement
with the findings of Clancy et al. [34] and Ghosh et al. [35],
who showed that NO inactivates COX-2 functions through
inhibiting its enzymatic activity by reacting with iron in the
enzyme’s heme group. Moreover, we demonstrated that
L-NAME, an inhibitor of NO synthases which decreased
NO level and motility of tumor cells in the experiment had
a relatively weak effect on COX-2 level. These results are
in agreement with the findings of other authors showing a
balance and interference with each other’s synthesis
between NO, COX-2 and PGE2 [36, 37]. These interactions
are important for maintaining homeostasis in normal cells
and influence invasiveness in tumors. There exist contra-
dictory reports describing the relationships between NO
and COX, showing that blockade of NOS by L-NAME
may either increase or decrease COX-2 and PGE2 synthesis
[38–40]. We suppose, on the basis of our study, that the NO
and COX-2 relationship is closely dependent on the kind of
cells that have been used, their direct interactions, the kind of
inhibitor applied and the local microenvironmental condi-
tions. These elements together influence COX-2 and PGE2
synthesis after NO imbalance. This hypothesis is confirmed
by Ohno et al. [40], who showed that mucosal PGE2 was
decreased by SC-560, a COX-2 inhibitor, but not by L-
NAME. Moreover, other authors have shown that L-NAME
reduces PGE2 generation via limitation of COX-2 expression
[41]. Therefore, L-NAME may limit the invasion and
migration of tumor cells and serve as a cancer prevention
factor [10, 42]. Finally, NS398, a specific COX-2 inhibitor,
decreased the enzyme and PGE2 levels and tumor cell
motility with slight effects on NO production. These results
are in agreement with the findings of West et al. [43]a n d
Payá et al. [44], who revealed that NS398 strongly reduced
COX-2 and PGE2 levels without affecting NO metabolites
and NOS activity. We can only speculate on the mechanism
by which COX-2 inhibitor also causes inhibition of the
enzyme expression. It may be associated with cell cycle
arrest by COX-2 inhibitor what may result in potential
decrease in enzyme level. NS398, which acts by inducing a
conformational change of COX-2, may also lead to
unrecognizing of the protein by specific antibodies. The
inhibitor may also cross-influence on molecular pathways
and signal transduction connected with enzyme activity
and expression. Finally there may be a feedback between
COX-2 and PGE2 levels and activity. However, these are
only speculations which need experimental confirmation.
Moreover, there is strong evidence indicating that specific
COX-2 inhibition could down-regulate the antiapoptotic
Bcl-2 protein, thus inhibiting proliferation and progression
of different carcinomas including colon cancer [14, 45,
46]. At present, there is no uniform explanation of the
mechanism of the cross-talks between NO and COX-2 and
PGE2 in tumor/normal cell co-cultures. Some evidence
indicates that NO produced from L-arginine contributes to
COX-2 and PGE2 activation [47]. However, no answer has
been offered to the question of the influence of the
NO+O2
− product (ONOO
−), which is locally produced
during direct tumor/normal cell interactions, on COX-2
expression. In our previous work we showed that during
direct tumor/normal cell contact O2
− anion is overproduced
[18]. However, our data obtained so far do not allow to
determine whether this is mainly free NO or its reaction
product peroxynitric acid, generated through the interaction
between tumor cell-derived superoxide anions and NO. In
order to distinguish reaction products, additional methods
should be applied. Nevertheless, NO as a short-lived and
highly reactive molecule will be converted into nitrate, a
stable end product of NO, and will react with free oxygen
radicals forming reactive oxygen/nitrogen species. The
exact kind of molecules formed needs further studies. On
the other hand, a large number of experimental results
indicate that NO, under certain conditions, down-
regulates the prostaglandin biosynthetic pathway mainly
via COX-2 inhibition [48]. We showed that in tumor or
normal cell monocultures NO had no significant influence
on COX-2 and PGE2 expression. However, in specific
culture conditions when tumor cells directly interacted
with normal cells, especially myofibroblasts, the addition
of L-arginine resulted in a limitation of COX-2 expression;
PGE2 level was decreased when tumor cells were
implanted onto normal colon epithelium. Based on these
results, we may speculate that NO and COX-2 and PGE2
cross-talks should be considered in relation to the
experimental conditions and the cell culture model used.
In conclusion, we have shown the existence of cross-
talks among NO, COX-2 and PGE2. This relationship is
rather unidirectional where NO level influences COX-2 and
PGE2 levels. Moreover, any imbalances in NO level caused
by exogenous factors influence COX-2 and PGE2 amounts
depending on the kind of cells, their reciprocal interactions
and the local microenvironmental conditions. The knowl-
edge of these effects may be useful in limiting colon
carcinoma progression and invasion.
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